{'fraction_non_alphanumeric': 0.038461538461538464, 'fraction_numerical': 0.03353057199211045, 'mean_word_length': 5.265432098765432, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of elevated urinary enolase I levels in patients with endometriosis

Abstract Objective: The aim of this study is to validate and investigate the clinical value of urinary enolase I in patients with endometriosis. Methods: Urine samples of 39 patients with histologically confirmed endometriosis and 20 patients without endometriosis were collected. Western blot analysis and enzyme-linked immunosorbent assay were used to detect the increase of enolase I in patients’ urine. Results: Urinary enolase I expression corrected for creatinine ratio (non neuronal enolase (NNE)-Cr) was significantly greater in patients with endometriosis (p = 0.026). When the diagnostic performance of NNE-Cr was evaluated with serum CA-125 combination, the area under the curve was 0.821 (95% confidence interval 0.713–0.928) with sensitivity and specificity of 76.9% and 85.0%, respectively. Conclusion: Elevated urinary enolase I, in conjunction with serum CA-125, may be used as a potential biomarker for endometriosis.